Tuesday, September 16, 2025

Artificial Intelligence Meets Psychedelics – The Daily Dive feat Fabio Chianelli

Today on the Daily Dive, Fabio Chianelli, CEO of PharmaTher Inc (CSE: PHRM) sits down with our host Cassandra Leah to discuss the company as well as the psychedelic space in general. Within, he discusses his outlook for the growing psychedelic renaissance as well as the direction that PharmaTher is headed in terms of research and development.

Pharmather is one of the latest firms to begin trading on the Canadian Securities Exchange, with a focus on the psychedelic space. The company works to combine artificial intelligence with research and development to develop solutions for unmet medical needs with these psychedelic compounds. The company is currently focused on the brain and nervous system, with a number of target conditions already identified.

Check out the full interview below.


FULL DISCLOSURE: Pharmather is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Pharmather on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

New Found Gold: The Strategic Maritime Resources Purchase

Amex Exploration: Revised Perron PEA Has INSANE Economics

Aris Mining: The Multi Billion Dollar Soto Norte PFS

Recommended

Canadian Copper Secures $8 Million Lead Order From Ocean Partners As Part Of Larger Funding Round

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Related News

PharmaTher To Develop Digital Therapeutics Platform Focused On Psychedelic Therapies

Pharmather Inc (CSE: PHRM) this morning announced that it has amended its sponsored research agreement...

Tuesday, December 1, 2020, 07:36:07 AM

PharmaTher Sponsors Research For Novel Delivery Of Ketamine

PharmaTher Inc (CSE: PHRM) this morning announced that it has entered into a sponsored research...

Wednesday, March 24, 2021, 07:19:06 AM

PharmaTher Files Patent For Use Of Ketamine In Type 2 Diabetes, Obesity

PharmaTher Holdings (CSE: PHRM) has expanded its patent portfolio. The company this morning announced the...

Tuesday, April 27, 2021, 07:54:44 AM

PharmaTher To Raise $10.0 Million Via Institutional Investor Financing

PharmaTher Holdings (CSE: PHRM) this morning indicated that the company has secured a financing with...

Friday, September 24, 2021, 08:28:12 AM

PharmaTher: Maxim Initiates Coverage With US$1.50 Price Target

PharmaTher Holdings (CSE: PHRM) had its first initiation report that came out on June 28th....

Wednesday, June 30, 2021, 02:38:00 PM